Stem Cells, Vol 13, 22-31, Copyright © 1995 by AlphaMed Press

REVIEWS

Acute promyelocytic leukemia: from clinic to molecular biology

SJ Chen, ZY Wang and Z Chen
Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Second Medical University, China.

Acute promyelocytic leukemia (APL) is a good model for studying the human malignancies in that up to 90% of APL patients can achieve complete remission (CR) with a differentiation inducer, all-trans retinoic acid (ATRA). APL is also associated with a specific chromosomal translocation t(15;17) which fuses the retinoic acid receptor alpha (RAR alpha) gene with a chromosome 15q locus, PML. Recently the RAR alpha and the PML gene structural alterations in t(15;17) have been characterized. The heterogeneity of the PML rearrangements juxtaposes different PML gene portions to the same set of RAR alpha exons, producing two major PML-RAR alpha fusion mRNA isoforms. A retrotranscriptase/polymerase chain reaction (RT-PCR) analysis of the fusion transcripts has been developed which allows the detection of minimal residual disease during the clinical remission of APL. Molecular study showed PML-RAR alpha can form heterodimers with wild-type PML and RXR. Recently, PML has been shown to be one of the components of a nuclear body, POD. In APL, the normal organization of POD is disrupted by PML-RAR alpha, whereas ATRA treatment in vivo and in vitro can induce a reorganization of this organelle. Cytogenetic and molecular study allowed a variant translocation t(11;17) being recently discovered in a small subset of APL. This time RAR alpha is fused to a new gene, PLZF, on chromosome 11q23. It has been shown that the PLZF- RAR alpha, like PML-RAR alpha, has a "dominant negative" effect on the wild-type RAR-RXR. Clinical data obtained from a group of t(11;17) APL patients showed that these respond poorly to ATRA and could be grouped in a special clinical syndrome within APL. The comparison of the biological activities mediated by PML-RAR alpha and PLZF-RAR alpha may give new insights into the pathogenesis as well as the mechanisms of ATRA-induced differentiation in APL.

This article has been cited by other articles:

				S. Ohno, M. Yoshimoto, S. Honda, S. Miyachi, T. Ishida, F. Itoh, T. Endo, S. Chiba, and K. Imai The Antisense Approach in Amyloid Light Chain Amyloidosis: Identification of Monoclonal Ig and Inhibition of Its Production by Antisense Oligonucleotides in In Vitro and In Vivo Models J. Immunol., October 1, 2002; 169(7): 4039 - 4045. [Abstract] [Full Text] [PDF]

				S.-H. Hong, Z. Yang, and M. L. Privalsky Arsenic Trioxide Is a Potent Inhibitor of the Interaction of SMRT Corepressor with Its Transcription Factor Partners, Including the PML-Retinoic Acid Receptor {alpha} Oncoprotein Found in Human Acute Promyelocytic Leukemia Mol. Cell. Biol., November 1, 2001; 21(21): 7172 - 7182. [Abstract] [Full Text] [PDF]

				F. L. Coco, D. Diverio, B. Falini, A. Biondi, C. Nervi, and P. G. Pelicci Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia Blood, July 1, 1999; 94(1): 12 - 22. [Full Text] [PDF]

				M. Yu, J.-H. Tong, M. Mao, L.-X. Kan, M.-M. Liu, Y.-W. Sun, G. Fu, Y.-K. Jing, L. Yu, D. Lepaslier, et al. Cloning of a gene (RIG-G) associated with retinoic acid-induced differentiation of acute promyelocytic leukemia cells and representing a new member of a family of interferon-stimulated genes PNAS, July 8, 1997; 94(14): 7406 - 7411. [Abstract] [Full Text] [PDF]